CD20-Targeted Ξ±-Radionuclides Synergize with Immune Checkpoint Inhibition to Treat Murine Lymphoma.
O'Steen S, Lee SY, Comstock ML, Kehret AR, Lin Y, Hamlin DK, Dexter SL, Hippe DS, Gooley TA, Wilbur DS, Li Y, Walter RB, Till B, Orozco JJ, Green DJ| | PubMed
Influence of B cell-lineage targeted CAR-T cell therapy on humoral immunity and vaccine-induced antibody response.
Ozog S, Krantz EM, Tindbaek K, Munoz J, Liu WL, Chalal C, Pernikoff S, Yahya K, Stevens-Ayers T, Dasgupta S, Cowan AJ, Green DJ, Gauthier J, Till BG, Gardner RA, Shadman M, Bleakley M, Boeckh M, Boonyaratanakornkit J, Turtle CJ, Hill JA| | PubMed
Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models.
Liang EC, Jeon Y, Qiao Y, Wu X, Huang JJ, Portuguese AJ, Basom R, Torkelson A, Kirchmeier D, Braathen K, Cowan AJ, Shadman M, Hirayama AV, Till BG, Kimble EL, Wu Q, Gauthier J| | PubMed
Barriers to Investigator-Initiated Clinical Trial Enrollment in Frontline Large B-Cell Lymphoma.
Ho C, Kennedy N, Di M, Gopal AK, Lynch RC, Ng K, Wu QV, Poh C, Raghunathan V, Rasmussen H, Shadman M, Till BG, Ujjani CS, Smith SD| | PubMed
Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia.
Poh C, Chen X, Voutsinas J, Naresh K, Dizon JJ, Shadman M, Lynch RC, Till BG, Ujjani CS, Di M, Raghunathan V, Warren EH, Smith SD, Wu QV, Cherian S, Gopal AK| | PubMed
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials.
Portuguese AJ, Tuazon SA, Pont MJ, Cole GO, Sather BD, Song X, Thomas S, Wood BL, Blake M, Works MG, Shadman M, Liang EC, Wu VQ, Voutsinas JM, Gooley TA, Turtle CJ, Till BG, Coffey DG, Maloney DG, Libby EN, Chapuis AG, Milano F, Riddell SR, Green DJ, Cowan AJ| | PubMed
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas.
Poh C, Voutsinas JM, Shadman M, Lynch RC, Warren EH, Crimp CA, Till BG, Ujjani CS, Di M, Raghunathan V, Smith SD, Wu QV, Shinohara MM, Gopal AK| | PubMed
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up.
Tuazon SA, Portuguese AJ, Pont MJ, Cowan AJ, Cole GO, Sather BD, Song X, Thomas S, Wood BL, Blake M, Works MG, Shadman M, Liang EC, Wu QV, Voutsinas JM, Gooley TA, Turtle CJ, Till BG, Coffey DG, Maloney DG, Riddell SR, Green DJ| | PubMed
Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell Therapy.
Ng SK, Flaherty PW, Ancheta M, Tindbaek KA, Sekhon MK, Huang JJ, Portuguese AJ, Albittar A, Kopmar NE, Cowan AJ, Shadman M, Hirayama AV, Till BG, Cassaday RD, Turtle CJ, Liu C, Xie H, Leisenring WM, Gauthier J, Liang EC, Hill JA| | PubMed
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma.
Samples L, Sadrzadeh H, Frigault MJ, Jacobson CA, Hamadani M, Gurumurthi A, Strati P, Shouval R, Noy A, Riedell PA, Dahiya S, Maloney DG, Till BG, Hirayama AV, Gauthier J, Gopal AK, Smith SD, Poh C, Lynch R, Ujjani C, Di M, Raghunathan V, Shakib-Azar M, Naresh KN, Gooley TA, Yared J, Jain MD, Locke FL, Leslie LA, Epperla N, Ghosh M, Skarbnik A, Hill BT, Kamdar MK, Ortiz-Maldonado V, Martinez-Cibrian N, Shune L, Shadman M| | PubMed
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up.
Portuguese AJ, Huang JJ, Jeon Y, Taheri M, Albittar A, Liang EC, Hirayama AV, Kimble EL, Iovino L, Poh C, Gopal AK, Shadman M, Till BG, Milano F, Chapuis AG, Otegbeye F, Cassaday RD, Basom RS, Wu QV, Maloney DG, Gauthier J| | PubMed
Development and validation of predictive models of early immune effector cell-associated hematotoxicity.
Liang EC, Huang JJ, Portuguese AJ, Ortiz-Maldonado V, Albittar A, Wuliji N, Basom R, Jeon Y, Wu Q, Torkelson A, Kirchmeier D, Chutnik A, Pender B, Sorror M, Hill JA, Kopmar NE, Banerjee R, Cowan AJ, Green D, Gopal AK, Poh C, Shadman M, Hirayama AV, Till BG, Kimble EL, Iovino L, Chapuis AG, Otegbeye F, Cassaday RD, Milano F, Turtle CJ, Maloney DG, Gauthier J| | PubMed
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience.
HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
Krakow EF, Brault M, Summers C, Cunningham TM, Biernacki MA, Black RG, Woodward KB, Vartanian N, Kanaan SB, Yeh AC, Dossa RG, Bar M, Cassaday RD, Dahlberg A, Till BG, Denker AE, Yeung CCS, Gooley TA, Maloney DG, Riddell SR, Greenberg PD, Chapuis AG, Newell EW, Furlan SN, Bleakley M| | PubMed
Randomized study of induction with bendamustine-rituximab Β± bortezomib and maintenance with rituximab Β± lenalidomide for MCL.
Smith MR, Jegede OA, Martin P, Till BG, Parekh SS, Yang DT, Hsi ED, Witzig T, Dave S, Scott D, Hanson C, Kostakoglu Shields L, Abdel-Samad N, Casulo C, Bartlett NL, Caimi PF, Al Baghdadi T, Blum KA, Romer MD, Inwards DJ, Lerner RE, Wagner LI, Little RF, Friedberg JW, Leonard JP, Kahl BS| | PubMed
Erratum to: Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.
Woolston DW, Lee ND, Shadman M, Latorre-Esteves E, Tee XR, Fredrickson J, Kohrn BF, Ujjani C, Eckel A, Till B, Fang M, Radich J, Bozic I, Risques RA, Yeung CCS| | PubMed
Long-term Remissions Following CD20-Directed Chimeric Antigen Receptor-Adoptive T-cell Therapy.
Mo G, Lee SY, Coffey DG, Voillet V, Kirsch IR, Gottardo R, Smythe KS, Yeung CCS, Greenbaum A, Green DJ, Maloney DG, Till BG| | PubMed
Impact and Durability of the Affordable Care Act Medicaid Expansion on Lung Cancer Treatment.
Thosani DS, Till BM, Meredith LT, Kalra A, Barta JA, Okusanya OT, Evans NR, Grenda TR| | PubMed
Association Between Utilization of Services and Perioperative Outcomes for Lung Cancer Resection.
Thosani DS, Meredith LT, West R, Till BM, Rahman U, Mack SJ, Koeneman S, Okusanya OT, Evans NR, Grenda TR| | PubMed
Geographic Variation in the Utilization of Services Surrounding Lung Cancer Resection.
Thosani DS, Meredith LT, West R, Till BM, Rahman U, Mack S, Okusanya OT, Evans Iii NR, Grenda TR| | PubMed
Institutional Experience With Robotic Lobectomy After Neoadjuvant Immunotherapy and Chemotherapy.
Mack SJ, Rshaidat H, Ho A, Till BM, Collins ML, Whitehorn GL, Martin J, Jacob JD, Grenda TR, Evans NR, Okusanya OT| | PubMed
Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.
Woolston DW, Lee ND, Shadman M, Latorre-Esteves E, Tee XR, Fredrickson J, Kohrn BF, Ujjani C, Eckel A, Till B, Fang M, Radich J, Bozic I, Risques RA, Yeung CCS| | PubMed
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.
Banerjee R, Poh C, Hirayama AV, Gauthier J, Cassaday RD, Shadman M, Cowan AJ, Till BG, Green DJ, Kiem HP, Gopal AK, Maloney DG| | PubMed
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.
Hirayama AV, Kimble EL, Wright JH, Fiorenza S, Gauthier J, Voutsinas JM, Wu Q, Yeung CCS, Gazeau N, Pender BS, Kirchmeier DR, Torkelson A, Chutnik AN, Cassaday RD, Chapuis AG, Green DJ, Kiem HP, Milano F, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ| | PubMed
Brief Report: Nonmalignant Surgical Resection Among Individuals with Screening-Detected Versus Incidental Lung Nodules.
Till BM, Grenda T, Tidwell T, Wickes B, Shusted C, Ruane B, Okusanya O, Evans NR, Barta JA| | PubMed
Upper Hemisternotomy Versus Full Sternotomy for Replacement of the Supracoronary Ascending Aorta and Aortic Valve.
Shah VN, Binongo J, Wei J, Till BM, King C, McGee J, Plestis KA| | PubMed
Global Cardiac Surgical Volume and Gaps: Trends, Targets, and Way Forward.
Vervoort D, Lee G, Ghandour H, Guetter CR, Adreak N, Till BM, Lin Y| | PubMed
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL.
Liang EC, Albittar A, Huang JJ, Hirayama AV, Kimble EL, Portuguese AJ, Chapuis A, Shadman M, Till BG, Cassaday RD, Milano F, Kiem HP, Riddell SR, Turtle CJ, Maloney DG, Gauthier J| | PubMed
Access to Guideline Concordant Care for Node-Positive Non-Small Cell Lung Cancer in the United States.
Collins ML, Mack SJ, Whitehorn GL, Till BM, Grenda TR, Evans NR, Gordon SW, Okusanya OT| | PubMed
CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype.
Lee SY, Lee DH, Sun W, Cervantes-Contreras F, Basom RS, Wu F, Liu S, Rai R, Mirzaei HR, O'Steen S, Green DJ, Shadman M, Till BG| | PubMed
Individual- and neighborhood-level characteristics of lung cancer screening participants undergoing telemedicine shared decision making.
Shusted CS, Juon HS, Ruane B, Till B, Zeigler-Johnson C, McIntire RK, Grenda T, Okusanya O, Evans NR, Kane GC, Barta JA| | PubMed
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.
Ho C, Gopal AK, Till BG, Shadman M, Lynch RC, Cowan AJ, Wu QV, Voutsinas J, Rasmussen HA, Blue K, Ujjani CS, Cassaday RD, Fromm JR, Fang M, Smith SD| | PubMed
The Safety of Robotic Pneumonectomy.
Mack SJ, Collins ML, Till BM, Whitehorn GL, Martin J, Rshaidat H, Grenda T, Evans NR, Okusanya OT| | PubMed
Is wedge a dirty word? Demographic and facility-level variables associated with high-quality wedge resection.
Ξ³-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Cowan AJ, Pont MJ, Sather BD, Turtle CJ, Till BG, Libby EN, Coffey DG, Tuazon SA, Wood B, Gooley T, Wu VQ, Voutsinas J, Song X, Shadman M, Gauthier J, Chapuis AG, Milano F, Maloney DG, Riddell SR, Green DJ| | PubMed
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.
Lynch RC, Ujjani CS, Poh C, Warren EH, Smith SD, Shadman M, Till B, Raghunathan VM, Alig S, Alizadeh AA, Gulhane A, Chen DL, Tseng Y, Coye H, Shelby M, Ottemiller S, Keo S, Verni K, Du H, Vandermeer J, Gaston A, Rasmussen H, Martin P, Marzbani E, Voutsinas J, Gopal AK| | PubMed
Undifferentiated Pleomorphic Sarcoma of the Thoracic Aorta: A Diagnostic and Therapeutic Challenge.
Till BM, Java A, King C, Shah VN, Sundaram B, Jiang W, Nooromid MJ, Plestis KA| | PubMed
Robotic Minimally Invasive Esophagectomy.
Till BM, Grenda TR, Okusanya OT, Evans Iii NR| | PubMed
Defining risk factors for mortality after emergent hiatal hernia repair in the era of minimally invasive surgery.
Stop the Bleed: Airway Hemorrhage After Pulmonary Thromboendarterectomy?
Till BM, Tchantchaleishvili V, Rajagopal K| | PubMed
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
Iovino L, Wu QV, Voutsinas J, Panaite L, Mullane E, Lynch RC, Ujjani C, Smith SD, Gopal AK, Till BG, Milano F, Chow V, Gauthier J, Turtle CJ, Maloney DG, Shadman M| | PubMed
Cessation of Routine Jejunostomy Tube Placement at Time of Minimally Invasive Ivor Lewis Esophagectomy and Impact on Body Mass Index.
Till BM, Mandel J, Unal E, Juckett L, Grenda T, Okusanya O, Palazzo F, Chojnacki K, Evans NR| | PubMed
Hospital Utilization of Stereotactic Body Radiation Therapy and Rates of Surgical Refusal.
Till BM, Whitehorn G, Mack SJ, Thosani D, Rahman U, Grenda T, Evans NR, Okusanya OT| | PubMed
Characteristics of High-Volume Lung Segmentectomy Hospitals: A Propensity Score-Matched Analysis.
Mack SJ, Till BM, Huang C, Yang CJ, Grenda T, Evans NR, Okusanya O| | PubMed
Impact of stereotactic body radiation therapy volume on surgical patient selection, short-term survival, and long-term survival in early-stage non-small cell lung cancer.
Till BM, Mack S, Whitehorn G, Rahman U, Thosani D, Grenda T, Evans NR, Okusanya O| | PubMed
Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients.
Yuan S, Peng L, Liu Y, Till BG, Yan X, Zhang J, Zhu L, Wang H, Zhang S, Li H, Gao Q, Wang Z| | PubMed
Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy.
An M, Wang W, Zhang J, Till BG, Zhao L, Huang H, Yang Y, Li T, Han L, Zhang X, Qin P, Wang Y, Zhang M, Cui H, Gao Q, Wang Z| | PubMed
Race is a Risk Factor for the Deferral of Resection and Radiation for Early-Stage Lung Cancer.
Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies.
Huang H, Peng L, Zhang B, Till BG, Yang Y, Zhang X, Zhao L, Fu X, Li T, Han L, Qin P, Chen L, Yan X, Liu Y, Wang W, Ye Z, Li H, Gao Q, Wang Z| | PubMed
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma.
Panaite L, Wu QV, Voutsinas J, Mullane E, Chow VA, Lynch RC, Ujjani CS, Smith SD, Gopal AK, Poh C, Iovino L, Turtle CJ, Maloney DG, Till BG, Gauthier J, Shadman M| | PubMed
National trends in pectus excavatum repair: patient age, facility volume, and outcomes.
Mack SJ, Till BM, Huang C, Thosani D, Rahman U, Grenda T, Evans NR, Okusanya OT| | PubMed
The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
Ujjani C, Shadman M, Lynch RC, Tu B, Stevenson PA, Grainger C, Zhu H, Hill JA, Huang ML, Nielsen L, Poh C, Sorensen T, Gopal AK, Warren EH, Till BG, Lee S, Gausman D, Smith SD, Gooley T, Greninger A| | PubMed
Role of fibrosarcoma-induced CD11b+ myeloid cells and tumor necrosis factor-Ξ± in B cell responses.
Wang Z, Liu Y, Peng L, Till B, Liao Y, Yuan S, Yan X, Chen L, Fu Q, Qin Z| | PubMed
Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study.
Palomba ML, Till BG, Park SI, Morschhauser F, Cartron G, Marks R, Shivhare M, Hong WJ, Raval A, Chang AC, Penuel E, Popplewell LL| | PubMed
Facility-level national trends in racial disparities of surgical therapy for early-stage lung cancer.
Savitch SL, Grenda TR, Yi M, Till B, Mack S, Huang C, Barta JA, Evans NR, Okusanya OT| | PubMed
Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma.
Yang Y, Li J, Till BG, Wang J, Zhang B, Wang H, Huang H, Li T, Gao Q, Li H, Wang Z| | PubMed
Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.
Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B| | PubMed
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Lynch RC, Cassaday RD, Smith SD, Fromm JR, Cowan AJ, Warren EH, Shadman MS, Shustov A, Till BG, Ujjani CS, Libby EN, Philip M, Coye H, Martino CN, Bhark SL, Morris K, Rasmussen H, Behnia S, Voutsinas J, Gopal AK| | PubMed
The Robotic Collis Gastroplasty for Paraesophageal Hernia Repair.
Tuazon SA, Sandmaier BM, Gooley TA, Fisher DR, Holmberg LA, Becker PS, Lundberg SJ, Orozco JJ, Gopal AK, Till BG, Coffey DG, Nartea ME, Matesan MC, Pagel JM, Rajendran JG, Press OW, Bensinger WI, Green DJ| | PubMed
Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade.
Chow VA, Martin PS, Smith SD, Till BG, Graf SA, Edlefsen KL, Hannan LM, Mostaghel EA, Gopal AK| | PubMed
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.
Smith SD, Till BG, Shadman MS, Lynch RC, Cowan AJ, Wu QV, Voutsinas J, Rasmussen HA, Blue K, Ujjani CS, Shustov A, Cassaday RD, Fromm JR, Gopal AK| | PubMed
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.
Shadman M, Gauthier J, Hay KA, Voutsinas JM, Milano F, Li A, Hirayama AV, Sorror ML, Cherian S, Chen X, Cassaday RD, Till BG, Gopal AK, Sandmaier BM, Maloney DG, Turtle CJ| | PubMed
The Ξ±-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.
O'Steen S, Comstock ML, Orozco JJ, Hamlin DK, Wilbur DS, Jones JC, Kenoyer A, Nartea ME, Lin Y, Miller BW, Gooley TA, Tuazon SA, Till BG, Gopal AK, Sandmaier BM, Press OW, Green DJ| | PubMed
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Kim A, Stevenson P, Cassaday RD, Soma L, Fromm JR, Gopal AK, Smith SD, Till B, Lynch RC, Ujjani C, Shadman M, Warren EH, Menon M, Russell K, Tseng YD| | PubMed
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Chow VA, Gopal AK, Maloney DG, Turtle CJ, Smith SD, Ujjani CS, Shadman M, Cassaday RD, Till BG, Tseng YD, Warren EH, Shustov AR, Menon MP, Bhark S, Acharya UH, Mullane E, Hannan LM, Voutsinas JM, Gooley TA, Lynch RC| | PubMed
Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.
Geer M, Roberts E, Shango M, Till BG, Smith SD, Abbas H, Hill BT, Kaplan J, Barr PM, Caimi P, Stephens DM, Lin E, Herrera AF, Rosenbaum E, Amengual JE, Boonstra PS, Devata S, Wilcox RA, Kaminski MS, Phillips TJ| | PubMed
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.
Cooper JP, Khajaviyan S, Smith SD, Maloney DG, Shustov AR, Warren EH, Soma LA, Lynch RC, Ujjani C, Till B, Halpern AB, Gopal AK, Deeg HJ, Scott BL, Shadman M| | PubMed
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, Li D, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Acharya UH, Cassaday RD, Chapuis AG, Dhawale TM, Hendrie PC, Kiem HP, Lynch RC, Ramos J, Shadman M, Till BG, Riddell SR, Maloney DG, Turtle CJ| | PubMed
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, Gooley TA, Cherian S, Chen X, Pender BS, Hawkins RM, Vakil A, Steinmetz RN, Schoch G, Chapuis AG, Till BG, Kiem HP, Ramos JD, Shadman M, Cassaday RD, Acharya UH, Riddell SR, Maloney DG, Turtle CJ| | PubMed
Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.
Smith SD, Reddy P, Sokolova A, Chow VA, Lynch RC, Shadman MA, Till BG, Shustov AR, Warren EH, Ujjani CS, Menon MP, Tseng YD, Gopal AK| | PubMed
Who is pirating medical literature? A bibliometric review of 28 million Sci-Hub downloads.
Till BM, Rudolfson N, Saluja S, Gnanaraj J, Samad L, Ljungman D, Shrime M| | PubMed
Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human TΒ cells.
Mirzaei HR, Jamali A, Jafarzadeh L, Masoumi E, Alishah K, Fallah Mehrjardi K, Emami SAH, Noorbakhsh F, Till BG, Hadjati J| | PubMed
Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.
Smith SD, Gandhy S, Gopal AK, Reddy P, Shadman M, Till BG, Lynch RC, Kanan S, Cowan A, Low L, Hill BT| | PubMed
Predictive and therapeutic biomarkers in chimeric antigen receptor T-cell therapy: A clinical perspective.
Mirzaei HR, Mirzaei H, Namdar A, Rahmati M, Till BG, Hadjati J| | PubMed
Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma.
Greenbaum AM, Green DJ, Holmberg LA, Gooley T, Till BG, Budde LE, Rasmussen H, Press OW, Gopal AK| | PubMed
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Combination of Cytokine-Induced Killer Cells and Programmed Cell Death-1 Blockade Works Synergistically to Enhance Therapeutic Efficacy in Metastatic Renal Cell Carcinoma and Non-Small Cell Lung Cancer.
Wang Z, Liu X, Till B, Sun M, Li X, Gao Q| | PubMed
Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.
Lee SY, Olsen P, Lee DH, Kenoyer AL, Budde LE, O'Steen S, Green DJ, Heimfeld S, Jensen MC, Riddell SR, Press OW, Till BG| | PubMed
Walking blood banks: an immediate solution to rural India's blood drought.
Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Tseng YD, Stevenson PA, Cassaday RD, Cowan A, Till BG, Shadman M, Graf SA, Ermoian R, Smith SD, Holmberg LA, Press OW, Gopal AK| | PubMed
Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy.
Reddy P, Kanan S, Cowan A, Warren H, Till B, Shadman M, Cassaday R, Press O, Shustov A, Gopal A, Smith SD| | PubMed
Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells.
Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.
O'Steen S, Green DJ, Gopal AK, Orozco JJ, Kenoyer AL, Lin Y, Wilbur DS, Hamlin DK, Fisher DR, Hylarides MD, Gooley TA, Waltman A, Till BG, Press OW| | PubMed
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.
Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR| | PubMed
Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.
Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SH, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, O'Steen S, Orcutt KD, Wilbur DS, Wittrup KD, Press OW| | PubMed
Prospects for chimeric antigen receptor (CAR) Ξ³Ξ΄ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
Mirzaei HR, Mirzaei H, Lee SY, Hadjati J, Till BG| | PubMed
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
Rufener GA, Press OW, Olsen P, Lee SY, Jensen MC, Gopal AK, Pender B, Budde LE, Rossow JK, Green DJ, Maloney DG, Riddell SR, Till BG| | PubMed
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW| | PubMed
Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Smith SD, Libby EN, Maloney DG, Press OW, Gopal AK| | PubMed
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, Holmberg LA, Till BG, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN, Bensinger WI, Shadman M, Maloney DG, Press OW, Gopal AK| | PubMed
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.
Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur DS, Balkan ER, Lin Y, Miller BW, Frost SH, Gopal AK, Orozco JJ, Gooley TA, Laird KL, Till BG, BΓ€ck T, Sandmaier BM, Pagel JM, Press OW| | PubMed
Brentuximab vedotin administered to platinum-refractory, transplant-naΓ―ve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
Onishi M, Graf SA, Holmberg L, Behnia S, Shustov AR, Schiavo K, Philip M, Libby EN, Cassaday RD, Pagel JM, Roden JE, Maloney DG, Green DJ, Till BG, Press OW, Smith SD, Gopal AK| | PubMed
T-cell immunotherapy: looking forward.
Corrigan-Curay J, Kiem HP, Baltimore D, O'Reilly M, Brentjens RJ, Cooper L, Forman S, Gottschalk S, Greenberg P, Junghans R, Heslop H, Jensen M, Mackall C, June C, Press O, Powell D, Ribas A, Rosenberg S, Sadelain M, Till B, Patterson AP, Jambou RC, Rosenthal E, Gargiulo L, Montgomery M, Kohn DB| | PubMed
Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.
Phipps C, Gopal AK, Storer BE, Cassaday RD, Press OW, Till BG, Pagel JM, Palanca-Wessels MC, Philip M, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Chauncey T, Maloney DG, Libby EN| | PubMed
Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma.
Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, Brouns SA, Spencer DM, Till BG, Jensen MC, Riddell SR, Press OW| | PubMed
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.
Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC, Philip M, Bensinger WI, Holmberg LA, Shustov A, Green DJ, Libby EN, Maloney DG, Gopal AK| | PubMed
Management of mantle cell lymphoma in the elderly.
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Maloney DG, Gopal AK| | PubMed
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.
James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Budde LE, Till BG, Raubitschek AA, Forman SJ, Press OW| | PubMed
Treatment of lymphoma with adoptively transferred T cells.
PubMed